Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-07-25
1999-11-30
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530328, 514 13, 514 2, A61K 3800
Patent
active
059943092
ABSTRACT:
A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.
REFERENCES:
Smith E.A.: "Peptides, chemistry and biology, Proceedings 12.sup.th APS, 1991 Cambridge" 1992, ESCOM, LEIDEN XP002083073 Lie e.a.: The inhibition of fibrin stimulated t-PA-induced plasminogen activation by the A chain fragment 149-157 or urokinase; see pp. 810-811, esp. table 1.
Wiley, R.A., et al., "Peptidomimetic Derived from Natural Products," Medicinal Research Reviews (1993) 13(3):328-384.
Claeson, G., "Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system," Blood Coagulation and Fibrinolysis (1994) 5:411-436.
Hruby, V.J., "Conformational and Topographical Considerations in the Design of Biologically Active Peptides," Biopolymers (1993) 33:1073-1082.
Kempf, D.J., "Design of Symmetry-Based, Peptidomimetic Inhibitors of Human Immunodeficiency Virus Protease," Methods in Enzymology (1994) 241:334-354.
Parish, C.R., et al., "A Basement-Membrane Permeability Assay which Correlates with the Metastatic Potential of Tumour Cells," Int. J. Cancer (1992) 52:378-383.
Hoosein, N.M., et al., "Involvement of Urokinase and its Receptor in the Invasiveness of Human Prostatic Carcinoma Cell Lines," Cancer Communications (1991) 3(8):255-264.
Chambers, S.K., et al., "Macrophage Colony-stimulating Factor Mediates Invasion of Ovarian Cancer Cells through Urokinase," Cancer Research (1995) 55:1578-1585.
Rabbani, S.A., et al., "Prevention of Prostate-Cancer Metastasis in vivo by a Novel Synthetic Inhibitor of Urokinase-type Plasminogen," Int. J. Cancer (1995) 63:840-845.
Min, H.Y., et al., "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," Cancer Research (1996) 56:2428-2433.
Schnaper, H.W., et al., "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," Journal of Cellular Physiology (1995) 165:107-118.
Odedra, R., et al., "Low Molecular Weight Angiogenesis Factors," Pharmac. Ther. (1991) 49:111-124.
Jones Terence R.
Mazar Andrew P.
Angstrom Pharmaceuticals, Inc.
Bansal Geetha P.
Hutzell Paula K.
Livnat Shmuel
LandOfFree
Anti-invasive and anti-angiogenic compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-invasive and anti-angiogenic compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-invasive and anti-angiogenic compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672642